These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

854 related articles for article (PubMed ID: 33306195)

  • 21. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High CD56++CD16- natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort.
    Bayigga L; Nabatanzi R; Sekiziyivu PN; Mayanja-Kizza H; Kamya MR; Kambugu A; Olobo J; Kiragga A; Kirimunda S; Joloba M; Nakanjako D
    BMC Immunol; 2014 Jan; 15():2. PubMed ID: 24483185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased expression of TIGIT and KLRG1 correlates with impaired CD56
    Nie Y; Liu D; Yang W; Li Y; Zhang L; Cheng X; Chen R; Yuan B; Zhang G; Wang H
    Virol J; 2022 Apr; 19(1):68. PubMed ID: 35413989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation.
    Roberts A; Bentley L; Tang T; Stewart F; Pallini C; Juvvanapudi J; Wallace GR; Cooper AJ; Scott A; Thickett D; Lugg ST; Bancroft H; Hemming B; Ferris C; Langman G; Robinson A; Chapman J; Naidu B; Pinkney T; Taylor GS; Brock K; Stamataki Z; Brady CA; Curnow SJ; Gordon J; Qureshi O; Barnes NM
    Sci Rep; 2021 Feb; 11(1):4030. PubMed ID: 33597595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The early expansion of anergic NKG2A
    Roberto A; Di Vito C; Zaghi E; Mazza EMC; Capucetti A; Calvi M; Tentorio P; Zanon V; Sarina B; Mariotti J; Bramanti S; Tenedini E; Tagliafico E; Bicciato S; Santoro A; Roederer M; Marcenaro E; Castagna L; Lugli E; Mavilio D
    Haematologica; 2018 Aug; 103(8):1390-1402. PubMed ID: 29700172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis.
    Fleury M; Belkina AC; Proctor EA; Zammitti C; Simms RW; Lauffenburger DA; Snyder-Cappione JE; Lafyatis R; Dooms H
    Arthritis Rheumatol; 2018 Apr; 70(4):566-577. PubMed ID: 29245183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.
    Pievani A; Borleri G; Pende D; Moretta L; Rambaldi A; Golay J; Introna M
    Blood; 2011 Sep; 118(12):3301-10. PubMed ID: 21821703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.
    Schoenfeld JD; Gjini E; Rodig SJ; Tishler RB; Rawal B; Catalano PJ; Uppaluri R; Haddad RI; Hanna GJ; Chau NG; Rabinowits G; Lorch J; Jo VY; Krane JF; Goguen LA; Annino DJ; Abdelrahman S; Lipschitz M; Margalit DN
    Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):137-145. PubMed ID: 29960819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.
    Jo W; Won T; Daoud A; Čiháková D
    Front Immunol; 2024; 15():1340373. PubMed ID: 38375475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD.
    Wiesmayr S; Webber SA; Macedo C; Popescu I; Smith L; Luce J; Metes D
    Eur J Immunol; 2012 Feb; 42(2):541-50. PubMed ID: 22105417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human NK cells proliferate and die in vivo more rapidly than T cells in healthy young and elderly adults.
    Lutz CT; Karapetyan A; Al-Attar A; Shelton BJ; Holt KJ; Tucker JH; Presnell SR
    J Immunol; 2011 Apr; 186(8):4590-8. PubMed ID: 21402893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of immune checkpoints in T cells of esophageal cancer patients.
    Xie J; Wang J; Cheng Sh; Zheng L; Ji F; Yang L; Zhang Y; Ji H
    Oncotarget; 2016 Sep; 7(39):63669-63678. PubMed ID: 27577071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.
    Nagato T; Ohkuri T; Ohara K; Hirata Y; Kishibe K; Komabayashi Y; Ueda S; Takahara M; Kumai T; Ishibashi K; Kosaka A; Aoki N; Oikawa K; Uno Y; Akiyama N; Sado M; Takei H; Celis E; Harabuchi Y; Kobayashi H
    Cancer Immunol Immunother; 2017 Jul; 66(7):877-890. PubMed ID: 28349165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1 Mediates Dysfunction in Activated PD-1
    Concha-Benavente F; Kansy B; Moskovitz J; Moy J; Chandran U; Ferris RL
    Cancer Immunol Res; 2018 Dec; 6(12):1548-1560. PubMed ID: 30282672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade.
    Ma L; Gai J; Qiao P; Li Y; Li X; Zhu M; Li G; Wan Y
    Biochem Biophys Res Commun; 2020 Oct; 531(2):144-151. PubMed ID: 32782142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TIGIT expression is upregulated in T cells and causes T cell dysfunction independent of PD-1 and Tim-3 in adult B lineage acute lymphoblastic leukemia.
    Zhang X; Zhang H; Chen L; Feng Z; Gao L; Li Q
    Cell Immunol; 2019 Oct; 344():103958. PubMed ID: 31376919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
    Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
    Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamics of TIGIT and PD-1 expression on NK cells during the course of normal pregnancy.
    Wang Y; Li D; Yu T; Hu M; Xing J; Bai S; Qu W; Tong X
    Immunol Lett; 2021 Feb; 230():42-48. PubMed ID: 33359535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD56
    Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
    Front Immunol; 2019; 10():14. PubMed ID: 30761123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.